Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Has Consensus Price Target of $683.64 According to Analysts

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Get Free Report) have received a consensus rating of “Moderate Buy” from the twenty-nine analysts that are covering the stock, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating, twenty-three have assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $683.64.

A number of research analysts recently issued reports on the stock. TD Cowen lifted their price target on shares of Thermo Fisher Scientific from $760.00 to $810.00 and gave the company a “buy” rating in a research report on Thursday, October 22nd. Barclays upped their price objective on shares of Thermo Fisher Scientific from $750.00 to $775.00 and gave the stock an “overweight” rating in a report on Thursday, October 22nd. The Goldman Sachs Group raised their target price on shares of Thermo Fisher Scientific from $650.00 to $780.00 and gave the company a “buy” rating in a research note on Monday, September 21st. Rothschild & Co Redburn lifted their target price on shares of Thermo Fisher Scientific from $725.00 to $750.00 and gave the company a “buy” rating in a report on Thursday, October 22nd. Finally, Royal Bank Of Canada lifted their target price on shares of Thermo Fisher Scientific from $580.00 to $730.00 and gave the company a “sector perform” rating in a report on Thursday, October 22nd.

Read Our Latest Research Report on TMO

Thermo Fisher Scientific News Roundup

Here’s some of the latest news about TMO:

  • Positive Sentiment: A report discusses Thermo Fisher’s $5 billion buyback, putting its cash generation and capital returns in focus. Repurchases can support per-share results and signal confidence, though the article also questions whether cash flows justify expectations after the stock’s strong multiyear return. Is Thermo Fisher Scientific Reasonable After Its $5 Billion Buyback?
  • Positive Sentiment: Coverage highlights Thermo Fisher as a supplier to cell-sheet gene-therapy developers, extending its relevance in regenerative medicine. This could create opportunities as the field develops, although the article does not quantify near-term revenue impact. Thermo Fisher Scientific, Why Is It Back In The Spotlight?
  • Neutral Sentiment: Other coverage notes TMO’s strong recent share performance and considers whether its cash generation can sustain investor expectations. That highlights potential valuation sensitivity, but provides no new earnings warning or negative company announcement. What Happened To People Who Bought Thermo Fisher Stock At A High?

Insiders Place Their Bets

In other Thermo Fisher Scientific news, VP Lisa Britt sold 11,440 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the transaction, the vice president owned 14,784 shares in the company, valued at approximately $9,064,366.08. The trade was a 43.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marc Casper sold 10,000 shares of the business’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $629.27, for a total value of $6,292,700.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares in the company, valued at $77,982,284.75. This trade represents a 7.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 24,546 shares of company stock valued at $15,479,192 in the last quarter. 0.33% of the stock is owned by company insiders.

Institutional Trading of Thermo Fisher Scientific

Several institutional investors have recently bought and sold shares of the company. Legacy Wealth Managment LLC ID lifted its stake in shares of Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after buying an additional 22 shares in the last quarter. Kilter Group LLC bought a new stake in shares of Thermo Fisher Scientific during the second quarter valued at approximately $25,000. Allied Private Wealth LLC purchased a new position in Thermo Fisher Scientific in the 2nd quarter worth approximately $26,000. Compass Financial Management LLC raised its holdings in Thermo Fisher Scientific by 137.5% in the 3rd quarter. Compass Financial Management LLC now owns 38 shares of the medical research company’s stock worth $26,000 after acquiring an additional 22 shares during the last quarter. Finally, Pingora Partners LLC bought a new position in Thermo Fisher Scientific in the 2nd quarter valued at approximately $30,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

TMO opened at $699.55 on Friday. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.71. The company has a market cap of $259.20 billion, a price-to-earnings ratio of 29.03, a price-to-earnings-growth ratio of 2.92 and a beta of 0.84. The stock has a fifty day simple moving average of $669.20 and a two-hundred day simple moving average of $556.44. Thermo Fisher Scientific has a 12-month low of $435.27 and a 12-month high of $727.56.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last announced its earnings results on Wednesday, October 21st. The medical research company reported $6.68 EPS for the quarter, beating analysts’ consensus estimates of $6.40 by $0.28. The firm had revenue of $12.14 billion for the quarter, compared to analysts’ expectations of $11.95 billion. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The company’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $5.79 EPS. Research analysts predict that Thermo Fisher Scientific will post 25.27 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 15th. Investors of record on Tuesday, December 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.92%.

About Thermo Fisher Scientific

(Get Free Report)

Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research. The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.

Further Reading

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.